Psoriasis

Kindred spoke with Dermatology Times to discuss AbbVie's recent Science of Skin event and improving access to equitable dermatological care.

Researchers linked higher exposure to natural environments and green spaces with an increased risk of developing psoriasis.

Increased COPD prevalence in patients with psoriasis likely reflects smoking correlation, according to researchers.

Both 8-week and 16-week dosing intervals of guselkumab achieved similar clinical outcomes and patient-reported responses in the GUIDE trial.

Alumis' Martin Babler shared insights into the program for the TYK2 inhibitor and the company's next steps for its development.

Skin with vitiligo and psoriasis shows increased immune cell type, with a Mendelian analysis finding no causal link between the conditions.

Researchers suggested that early intervention with less than 2 years of disease duration was associated with a lower risk of relapse.

A recent review called for gender-specific studies to enhance dermatological treatments and potentially revise guidelines.

An expert dermatologist explores personalized psoriasis treatment strategies, emphasizing patient education on realistic treatment response expectations and proper application techniques to enhance therapeutic efficacy.

A board-certified dermatologist examines evidence-based strategies for managing plaque psoriasis, focusing on personalized non-steroidal treatment options to optimize patient outcomes.

A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.

Medical experts explore approaches for addressing suboptimal outcomes in systemic psoriasis treatments, including methods to enhance therapeutic efficacy and criteria for transitioning to alternative treatments.

Dermatology experts examine the role of IL-17 inhibitors in psoriasis management, focusing on treatment strategies, swift clinical responses, and their effectiveness across various anatomical sites affected by plaque psoriasis.

Researchers behind the phase 3 studies gave pearls into the study methods, results, and what is up next.

The submission to the FDA is supported by positive results from the ARRECTOR phase 3 trial.

Oral dimethyl fumarate improved all disease classification criteria for plaque psoriasis, showing significant betterment of severity and quality of life.

A recent study found that patients with genital psoriasis involvement are more likely to have involvement in other special body areas, such as the scalp.

Medical professionals discuss ongoing clinical trials and novel medications for the treatment of psoriasis.

Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.

Diamant Thaçi, MD, PhD, shares insights on the data presented at the World Psoriasis & Psoriatic Arthritis (IFPA) Conference.

The increasing prevalence of this chronic condition in children necessitates understanding its broader impacts and management strategies.

Ben Lockshin, MD, FAAD, shared his insights on the latest advancements in oral options for psoriasis therapies.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

This professional summary discusses the definitions of loss of response and loss of efficacy in patient therapy, while also comparing response rates across different psoriasis treatments.

Key opinion leaders examine patient response rates to biologic treatments and provide critical insights on transitioning between therapies to optimize patient outcomes.

Christopher Bunick, MD, PhD, provides insights into new research exploring bimekizumab’s unique binding to IL-17F and IL-17A by analyzing crystals of bimekizumab fragment antigen-binding.

Phase 3 trials found the treatment demonstrated efficacy as early as week 1 of treatment and sustained this response through week 52.

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Key opinion leaders explore the management of plaque psoriasis, addressing treatment-related challenges and emphasizing the importance of effective communication for informed decision-making in therapy selection.

Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.